Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 1.08B +374.4% |
| Revenue (ttm) | n/a |
| Net Income | -44.17M |
| EPS | -0.55 |
| Shares Out | 84.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,036,262 |
| Open | 12.35 |
| Previous Close | 12.19 |
| Day's Range | 12.09 - 12.80 |
| 52-Week Range | 3.38 - 26.95 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 33.33 (+158.77%) |
| Earnings Date | May 7, 2026 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price target is $33.33, which is an increase of 158.77% from the latest price.
News
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership te...
Corvus Pharmaceuticals Transcript: Study update
Soquelitinib demonstrated rapid, deep, and durable clinical responses in moderate to severe atopic dermatitis, with a clean safety profile and no rebound after treatment. Mechanistic data show selective immune modulation and increased Tregs, supporting potential disease modification and broad applicability.
Corvus Pharmaceuticals Press release: Study update
Corvus Pharmaceuticals issued a press release on May 14, 2026, disclosing material business information to investors.
Corvus Pharmaceuticals Slides: Study update
Corvus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential fo...
Corvus Pharmaceuticals reports Q1 EPS (15c), consensus (15c)
“We started the year with strong momentum for soquelitinib, our selective ITK inhibitor that we believe is well positioned to improve therapy for a broad range of patients with atopic…
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting t...
Corvus Pharmaceuticals Earnings release: Q1 2026
Corvus Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Corvus Pharmaceuticals Quarterly report: Q1 2026
Corvus Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Corvus Pharmaceuticals Proxy statement: Proxy filing
Corvus Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Corvus Pharmaceuticals Proxy statement: Proxy filing
Corvus Pharmaceuticals filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.
SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D...
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free re...
Corvus Pharmaceuticals initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $40 price target The shares trade at an attractive entry point given the company’s “leading emerging” oral…
Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer
Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $33 from $32 and keeps an Outperform rating on the shares after the company reported full year 2025 results…
Corvus Pharmaceuticals files automatic mixed securities shelf
08:03 EDT Corvus Pharmaceuticals (CRVS) files automatic mixed securities shelf
Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025
Soquelitinib showed strong efficacy and durable responses in atopic dermatitis and PTCL, with robust safety and broad applicability. Financial position is solid after a $200M financing, supporting an expanded clinical pipeline and cash runway into 2028.
Corvus Pharmaceuticals Annual report: Q4 2025
Corvus Pharmaceuticals has published its Q4 2025 annual report on March 12, 2026.
Corvus Pharmaceuticals Earnings release: Q4 2025
Corvus Pharmaceuticals released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Corvus Pharmaceuticals reports Q4 EPS (15c), consensus (13c)
“We believe the recent cohort 4 data from our Phase 1 atopic dermatitis trial demonstrate that soquelitinib has the potential to be an important new medicine for a broad range…
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy
Corvus Pharmaceuticals Slides: Corporate presentation
Corvus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2026.
Corvus Pharmaceuticals options imply 7.9% move in share price post-earnings
Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 7.9%, or $1.28, after results ar...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals options imply 5.5% move in share price post-earnings
Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:1. Implied volatility suggests the market is anticipating a move near 5.5%, or 99c, after results are…